Trial Profile
Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Zirconium-89 DFO-trastuzumab (Primary)
- Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms ZEPHIR
- 20 Apr 2024 This trial has been completed in Netherlands (Global end date: 28 Mar 2024), according to European Clinical trial database record.
- 11 Apr 2024 This trial has been completed in Belgium (Global end date: 28 Mar 2024).
- 09 Aug 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.